The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses.
Phase 1 Study in 12 pediatric patients with recurrent high grade glioma (HGG)
- Improved overall survival 12.2 months versus 5.6 months for historical trials
- Dramatic Safety Advantage – No serious adverse events
- Evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot”
- Original Article “Oncolytic HSV-1 G207 Immunotherapy for Pediatric High-Grade Glioamas” (Friedman GK) published in New England Journal of Medicine April 10, 2021
- Phase 1 data presented at American Association of Cancer Research (AACR) conference April 10, 2021 (Friedman GK)
Friedman – NEJM Article – April 2021
Phase 2 Clinical Trial of G207 in Children with Recurrent High-Grade Glioma
- 30 children with recurrent glioma
- Overall Survival measured against historical controls from prior pediatric HGG studies
- Safety, immune response, and radiographic responses also will be evaluated
Phase 1 Study of G207 in combination with 5Gy radiation in up to 15 patients with recurrent medulloblastoma and other cerebellar tumors.
Bernstock – Cerebellar Clinical Trial – Molecular Therapy 2020